Nurex S.r.l.   Report issue

For profit Phase 2
Founded: Sassari Italy (1994)
Status: Left NME R&D (2022)

Organization Overview

First Clinical Trial
2017
NCT03697668
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Nurex S.r.l.

Active Ingredients

Drugs in Phase 2 Trials (3)

dihydroartemisinin (1 trial)

imatinib (gleevec) (1 trial)

piperaquine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Malaria, Falciparum (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 3